Pacer Advisors
ANIK icon

Pacer Advisors’s Anika Therapeutics ANIK Stock Holding History

Pacer Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-645
Closed -$26K – 1414
2021
Q1 		$26K Buy
645
+40
+7% +$1.52K ﹤0.01% 1490
2020
Q4 		$27K Sell
605
-202
-25% -$7.67K ﹤0.01% 1468
2020
Q3 		$29K Buy
+807
New +$29.1K ﹤0.01% 1337
2020
Q2 		– Sell
-1,316
Closed -$43K – 944
2020
Q1 		$43K Buy
+1,316
New +$53.2K ﹤0.01% 557
2019
Q3 		– Sell
-2,953
Closed -$120K – 1177
2019
Q2 		$120K Sell
2,953
-1,145
-28% -$41.8K ﹤0.01% 1089
2019
Q1 		$124K Buy
4,098
+1,372
+50% +$47K ﹤0.01% 672
2018
Q4 		$92K Buy
2,726
+1,372
+101% +$49.5K ﹤0.01% 260
2018
Q3 		$57K Buy
1,354
+838
+162% +$33.1K ﹤0.01% 1137
2018
Q2 		$17K Buy
+516
New +$21.3K ﹤0.01% 1152

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pacer Advisors's ANIK Position: Q2 2021 in Review

Pacer Advisors sold out of Anika Therapeutics (ANIK) in Q2 2021, closing a stake of 645 shares — an estimated $26K sold.

Pacer Advisors first reported a position in ANIK in Q2 2018 and held it in 9 quarters. The position peaked at $124K in Q1 2019. 139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

  • Pacer Advisors reported no remaining Anika Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 645 Anika Therapeutics shares in Q2 2021, an estimated $26K.
  • Pacer Advisors first reported a position in Anika Therapeutics in Q2 2018 and held it in 9 quarters.
  • Pacer Advisors's Anika Therapeutics position peaked at $124K in Q1 2019.
  • 139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.